Archive for ‘Pharmaceuticals’
Biotech investors waiting for partnership announcements
Shares of PharmaGap (TSX: V.GAP) rallied 31% to 19 cents on Wednesday.
Small biotech stock pops on FDA approval
Shares of Nuvo Research (TSX: T.NRI) shot up 30% to 45 cents on Thursday as the drug development company and Covidien (NYSE: COV) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid Topical Solution (diclofenac sodium topical solution) 1.5% w/w. Pennsaid Topical Solution is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of the signs and symptoms of osteoarthritis of the knee.
Mask supplier surges on contract news
Noveko (TSX: T.EKO) shares shot up 39 cents or 17% to $2.68 at last check.
Biopharm stock soars on FDA ruling
Æterna Zentaris (TSX: T.AEZ) shares shot up 30% to $1.45 on Wednesday as the global biopharmaceutical firm focused on endocrine therapy and oncology announced that Keryx Biopharmaceuticals, its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Vasogen (VAS) climbs on merger news
Ontario-based Vasogen (TSX: T.VAS) announced Monday that it has entered into a definitive agreement to combine with privately-held specialty pharmaceutical company IntelliPharmaCeutics.
Transcept Pharma (TSPT) surges on agreement news
Shares of Transcept Pharmaceuticals (NASDAQ: TSPT) surged 43% to $8.30 Monday, as the company and Purdue Pharmaceutical Products announced that they have entered into an exclusive license and collaboration agreement to commercialize prescription sleep aid drug Intermezzo in the United States.
Response Biomedical (RBM) gets FDA clearance on virus test
In breaking news Wednesday, Vancouver-based Response Biomedical Corporation (TSX: T.RBM) announced that it received a U.S. FDA 510(k) clearance to market a rapid Respiratory Syncytial Virus test.
BioCryst (BCRX) surges on flu drug trial results
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX), the life-sciences component of Stockhouse wealth service Ticker Trax (TM), soared 41% to $5.95 Friday, after the Birmingham, Alabama-based biotech firm announced positive results from two Phase 3 studies of its influenza treatment, intravenous peramivir, in patients with seasonal flu.
Pharma firm’s shares jump on FDA approval news
Shares of Angiotech Pharmaceuticals (TSX: T.ANP) surged 29% to $2.09 Thursday, as the Vancouver-based company reported that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received U.S. FDA approval to market its TAXUS Liberté Long Paclitaxel-Eluting Coronary Stent System, a drug-eluting stent designed for long lesions.
